跳至主要内容
临床试验/NCT00647075
NCT00647075Unknown4 期

A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.

Hospital Clinic of Barcelona2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年11月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
入组人数
60
试验地点
2
主要终点
Mean change in signs and symptoms from baseline measured by Visual Analogue Scale (VAS)

研究概览

简要总结

The purpose of this study is to assess the effects of a dietary supplement, the traditional Asian mushroom Yunzhi, as adjuvant in the treatment of patients with breast cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Women with diagnosis of breast cancer
  • •Undergoing adjuvant/neoadjuvant chemotherapy with either FEC, FAC, TAC, or EC + docetaxel combinations.
  • •≥ 18 years of age
  • •Performance status: 0-2
  • •Ability to provide written informed consent

排除标准

  • •Any prior history of yunzhi use
  • •Use of other herbal remedies during the study duration
  • •Significant cardiac, pulmonary, renal, hepatic, gastrointestinal, CNS, psychiatric disease or illicit substance use/abuse that in the opinion of the investigator would make the participant a poor candidate for study participation
  • •Pregnancy (for women of childbearing potential, a negative pregnancy test, urine or serum, is required within 14 days prior to randomization)
  • •Systemic use of progestins, androgens or other steroids (dexamethasone is allowed if used as antiemetic therapy)

研究组 & 干预措施

1

Experimental

Yunzhi extract 3.5 g/day

干预措施: Yunzhi extract (Dietary Supplement)

2

Placebo Comparator

Placebo

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Mean change in signs and symptoms from baseline measured by Visual Analogue Scale (VAS)

时间窗: 6 months

次要结局

  • Treatment adherence Clinical and laboratory (including RBC, WBC and platelets) adverse events Adherence to chemotherapy schedule EPO and blood transfusion needs(6 months)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验